MedTrace Logo

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

NCT02718859 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-09-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporation（IRE）and nature killer(NK) cells for advanced pancreatic cancer.

Conditions

Interventions

BIOLOGICAL

NK cells

The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd

PROCEDURE

irreversible electroporation (IRE )

The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Niu, PhD · Fuda Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2017-03-01
Completion
2019-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718859 on ClinicalTrials.gov